A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggested big pharma may finally be willing to place ...

Discover AbbVie's standout Q2 2025 earnings insights, with strong Skyrizi & Rinvoq growth, raised revenue guidance, and robust R&D progress driving ...

AbbVie stock rose after the drugmaker reported second-quarter earnings per share of $2.97 on revenue of $15.4 billion, ...

AbbVie Inc. ABBV reported second-quarter 2025 adjusted EPS of $2.97, which beat the Zacks Consensus Estimate of $2.89. The ...

AbbVie Inc. (NYSE: ABBV) stock is up nearly 2% in midday trading after delivering a beat-and-raise in its second-quarter 2025 ...

The demand for dermal fillers is influenced by several major factors. First, the global increase in cosmetic procedures is largely driven by an aging population and a heightened desire to preserve a ...

Psychedelic stocks rise after report on AbbVie's (ABBV) deal talks to acquire Gilgamesh Pharmaceuticals in a transaction ...

Move over Humira, Skyrizi and Rinvoq are expected to beat the former megablockbuster’s peak sales by the end of this year.

AbbVie said on Thursday its tariff exposure is not expected to exceed that of rivals, and raised its 2025 profit forecast ...

As for its neuroscience portfolio, AbbVie has added $300 million, putting its projection for the year at $10.5 billion, which ...

AbbVie posted $15.42 billion in Q2 revenue, topping estimates, with strong immunology and neuroscience growth, while ...

AbbVie Inc. is in talks to acquire next-generation psychedelics developer Gilgamesh Pharmaceuticals, according to people ...